The interactive tool allows you to analyze and graph the Fresenius SE & Co. KGaA share price, including the performance of its ordinary shares (ORD) and its ADR program in the United States.
Contact
Vice President Investor Relations
Deputy Head of Investor Relations
T: +49 (0) 6172 608-5167
florian.feick@fresenius.com
Related Links
Interactive ToolFill out the fields and click "Show data". The Total Return Calculator will provide you with the current value of your Fresenius shares and the return. Moreover, the Calculator shows the share price performance during the selected period.
Contact
Vice President Investor Relations
Deputy Head of Investor Relations
T: +49 (0) 6172 608-5167
florian.feick@fresenius.com
Related Links
Interactive ToolMembers of the Supervisory Board of Fresenius SE & Co. KGaA
Member of various supervisory bodies
Chairman of the Supervisory Board of Fresenius SE & Co. KGaA
Initial appointment: 2021
Current term of office: 2025 – 2029


Date of Birth: | March 19, 1955 |
Place of Birth: | Bensberg |
Nationality: | German |
Professional Experience
2002 - 2018 | DZ Bank AG
|
2000 - 2002 | Deutsche Bank AG, Frankfurt
Managing Director and Senior Credit Executive of the Corporates and Real Estate Division and CIB Corporate and Investment Bank |
1998 - 2000 | Deutsche Bank, Singapore
General Manager and Chief Country Officer |
1981 - 1998 | Deutsche Bank AG, Düsseldorf and Frankfurt
Various positions within the Corporate and Investment Banking Division |
Education/Academic career
1977 - 1981 | Universität Köln
Business Administration (Diplom-Kaufmann) |
1975 - 1977 | Deutsche Bank AG
Banking apprenticeship |
Membership of other statutory supervisory boards | |
Adolf Würth GmbH & Co. KG | |
Membership of comparable German or foreign supervisory bodies | |
None |
Full-time Works Council Member
Helios Vogtland-Klinikum Plauen GmbH
Member of the Supervisory Board of Fresenius SE & Co. KGaA
Initial appointment: 2018
Current term of office: 2025 – 2029

Date of Birth: | October 1, 1958 |
Place of Birth: | Bad Elster |
Nationality: | German |
Professional Experience
since 09/2018 | Chairman of the Group Works Council Helios Kliniken GmbH |
since 2010 | Member of the European Works Council of Fresenius SE & Co. KGaA |
since 2006 | Helios Vogtland-Klinikum Full-time Works Council Member (Chairman) |
2003 - 2006 | Humaine Vogtland-Klinikum 50% Works Council Member (Chairman); 50% Degreed engineer, Department of biomedical engineering |
1990 - 2003 | Vogtland-Klinikum Plauen Degreed engineer
|
1985 - 1990 | Bezirkskrankenhaus Plauen Degreed engineer |
Education/Academic career
1980 - 1985 | Ilmenau University of Technology Engineering degree in Technical Cybernetics and Biomedical Engineering |
Membership of other statutory supervisory boards | |
Helios Vogtland-Klinikum Plauen GmbH (Fresenius Group mandate) | |
Membership of comparable German or foreign supervisory bodies | |
None |
Member of various Supervisory Boards
Deputy Chairman of the Supervisory Board of Fresenius SE & Co. KGaA
Initial appointment: 2015
Current term of office: 2025 – 2029

Date of Birth: | December 23, 1954 |
Place of Birth: | Bielefeld |
Nationality: | German |
Professional Experience
2003 - 2015 | Allianz SE (formerly Allianz AG) Chairman of the Management Board |
1998 - 2003 | Allianz AG Member of the Management Board |
1988 - 1998 | Allianz Versicherungs-AG |
1983 - 1988 | Diekmann / Thieme GbR (publishing house) CEO |
Education/Academic career
1973 - 1982 | University of Göttingen Studies in Law and Philosophy |
Membership of other statutory supervisory boards | |
Allianz SE1 (Chair) | |
Membership of comparable German or foreign supervisory bodies | |
None |
-
1 Stock listed company
Secretary of the Trade Union ver.di Vereinte Dienstleistungsgewerkschaft
Deputy Chair of the Supervisory Board of Fresenius SE & Co. KGaA
Initial appointment: 2020
Current term of office: 2025 – 2029

Date of Birth: | January 24, 1973 |
Place of BIrth: | Cottbus |
Nationality: | German |
Professional Experience
since 1991 | Trade Union Vereinte Dienstleistungsgewerkschaft ver.di
|
Education
1989 - 1991 | Lausitzer Braunkohle AG Apprenticeship as business management assistan |
Membership of other statutory supervisory boards | |
None | |
Membership of comparable German or foreign supervisory bodies | |
None |
Full-time Works Council Member
Helios Clinic Herzberg and Osterode GmbH
Member of the Supervisory Board of Fresenius SE & Co. KGaA
Initial appointment: 2025
Current term of office: 2025 – 2029

Date of Birth: | August 03, 1963 |
Place of Birth: | Northeim |
Nationality: | German |
Professional Experience
since 2021 | Member of the European Works Council of Fresenius SE & Co. KGaA
|
Since 2019 | Deputy Chair of the Group Works Council Helios Kliniken GmbH |
since 2014 | Helios Clinic Herzberg and Osterode GmbH
|
1998 – 2014 | Specialist nurse (from 1999) for nursing care in the surgical service Klinik Herzberg and Osterode GmbH (Rhön) |
1991 – 1998 | Nurse in the OR
|
4/83 – 03/91 | Temporary soldier
|
Education
1983 – 1986 | Training as a nurse |
1997 – 1999 | Training as a specialist nurse for nursing in the surgical service |
Membership of other statutory supervisory boards | |
None | |
Membership of comparable German or foreign supervisory bodies | |
None |
Chairman of the Board and Medical Director
of the Mainz University Medical Center
Member of the Supervisory Board of Fresenius SE & Co. KGaA
Initial appointment: 2025
Current term of office: 2025 – 2029

Date of Birth: | May 14, 1970 |
Place of Birth: | Wiesbaden |
Nationality: | German |
Professional Experience
since 2024 | Mainz University Medical Center Chairman of the Board and Medical Director |
2021 – 2023 | Helios Dr. Horst Schmidt Kliniken Wiesbaden Medical Director |
2014 – 2021 | Helios Dr. Horst Schmidt Kliniken Wiesbaden Gastroenterology Clinic Director, Medical Director |
2012 – 2014 | St. Marienkrankenhaus Frankfurt Chief Physician for Internal Medicine and Gastroenterology |
2008 – 2012 | Mainz University Medical Center W2 Professorship for Gastrointestinal Endoscopy |
Education/Academic career
2005 | Mainz University Medical Center Habilitation |
1996 | Mainz University Medical Center Promotion |
1990 – 1996 | Mainz University Medical Center Studies of human medicine |
Membership of other statutory supervisory boards | |
None | |
Membership of other statutory supervisory boards | |
None |
Full-time Works Council Member
Quirónsalud Hospital Universitari General de Catalunya
Senior trade union secretary of the UGT trade union
for the private healthcare sector Barcelona
Member of the Supervisory Board of Fresenius SE & Co. KGaA
Initial appointment: 2025
Current term of office: 2025 – 2029
Date of Birth: | May 25, 1984 |
Place of Birth: | Barcelona |
Nationality: | Spanish |
Professional Experience
since 2025 | Member of the European Works Council of Fresenius SE & Co. KGa |
since 02/2024 | Mediator and Conciliator of the UGT trade union Labor Court of Catalonia Barcelona, Barcelona |
since 06/2020 | General Secretary of the UGT trade union UGT representative for occupational health and safety Quirónsalud Hospital Universitari General de Catalunya San Cugat del Vallés, Barcelon |
since 01/2006 | Administration Emergency Department Quirónsalud Hospital Universitari General de Catalunya San Cugat del Vallés, Barcelona |
Education/Academic career
2008 - 2010 | Master‘s degree in secretarial and operational management Vapor Universitario de Terrassa, Barcelona |
2006 - 2008 | CFGS Administration and Finance IES Terrassa, Barcelona |
2004 - 2005 | CFGM Administrativa IES Santa Eulalia, Barcelona |
1996 - 2000 | Secondary school diploma I.E.S. Cavall Bernat, Barcelona |
Membership of other statutory supervisory boards | |
None | |
Membership of comparable German or foreign supervisory bodies | |
None |
Member of various supervisory bodies
Member of the Supervisory Board of Fresenius SE & Co. KGaA
Initial appointment: 2016
Current term of office: 2025 – 2029

Date of Birth: | November 17, 1960 |
Place of Birth: | Offenbach / Main |
Nationality: | German |
Professional Experience
2008 - 2024 | UCB S.A. Chief Medical Officer and Executive Vice President Development |
2001 - 2009 | Schwarz Pharma AG Member of the Executive Board, Head of Research and Development |
2000 - 2001 | BASF Pharma Vice President Global Projects |
1992 - 2000 | Hoechst AG Various positions, last serving as Vice President Clinical Development |
Education/Academic career
since 2000 | University of Frankfurt am Main Professor for internal medicine |
1985 | University of Frankfurt am Main Doctorate in medicine (Dr. med.) |
1979 - 1985 | University of Frankfurt am Main Studies of medicine |
Membership of other statutory supervisory boards | |
Evotec AG1 (Chair) | |
Membership of comparable German or foreign supervisory bodies | |
Sobi Swedish Orphan Biovitrum1 (Member of the Board of Directors) |
-
1 Stock listed company
Full-time Works Council Member
Fresenius Kabi Deutschland GmbH
Member of the Supervisory Board of Fresenius SE & Co. KGaA
Initial appointment: 2023
Current term of office: 2025 – 2029

Date of Birth: | May 18, 1969 |
Place of Birth: | Marburg |
Nationality: | German |
Professional Experience
since 2002 | Fresenius Kabi Deutschland GmbH, Standort Friedberg
|
since 2021 | Honorary Judge, Hessian Tax Court |
since 2017 | IHK-Examiner, IHK Frankfurt |
since 2015 | Honorary Judge, Labour Court |
2007 – 2018 | Laboratoy Manager, IPK-Laboratories |
2003 – 2007 | Quality Control Technician |
1992 – 2003 | Quality Control Laboratory Assistant |
Education
2021 | Specialist for Occupational Health Management, IHK |
2020 – 2021 | Certified Specialist for Data Protection and Data Security |
2018 | Project Manager, IHK |
1999 – 2001 | Training as Bachelor Professional of Management for Industry |
1985 – 1989 | Apprenticeship as Chemical Laboratory Technician |
Membership of other statutory supervisory boards | |
None | |
Membership of comparable German or foreign supervisory bodies | |
None |
Production staff member
Fresenius Kabi España S.A.U.
Member of the Supervisory Board of Fresenius SE & Co. KGaA
Initial appointment: 2016
Current term of office: 2025 – 2029

Date of Birth: | January 29, 1974 |
Place of Birth: | Barcelona |
Nationality: | Spanish |
Professional Experience
since 2008 | Member of the European Works Council of Fresenius SE & Co. KGaA |
since 2004 | Member of the Works Council Fresenius Kabi España S.A.U. |
since 1998 | Fresenius Kabi AG |
Education
2016 | Seminar at ETUI (European Trade Union Institute): Current challenges for employee representatives in supervisory boards: How to deal with confidentiality rules and impact of European commercial law |
2015 | Seminar: Trade union cultures in the European Union Training for the European Works Council (EWC training center) Seminar: Occupational Health and Safety (Trainig center of CC.OO.) |
1990 - 1994 | Instituto Cristófol Ferrer, Secondary school |
Membership of other statutory supervisory boards | |
None | |
Membership of comparable German or foreign supervisory bodies | |
None |
Member of various Supervisory Boards
Member of the Supervisory Board of Fresenius SE & Co. KGaA
Initial appointment: 2022
Current term of office: 2025 – 2029

Date of Birth: | February 28, 1961 |
Place of Birth: | Marl |
Nationality: | German |
Professional Experience
2012 - 2022 | Deutsche Beteiligungs AG, Frankfurt / Main Member of the Executive Board / Chief Financial Officer Responsible for Finance and Accounting, Investor Relations, Legal and Tax, Portfolio Valuation, Risk Management, Internal Audit, Human Resources, Organization, IT |
2011 – 2012 | Kirche in Not, Königstein im Taunus Managing Director at the global headquarter of the organization |
1990 – 2011 | KPMG AG, Frankfurt / Main Last position: partner
|
1987 - 1990 | Winterhager Dr. Heintges Stützel Laubach GmbH, Wirtschaftsprüfungsgesellschaft, Düsseldorf Last position: Auditor and tax specalist |
Education/Academic career
1995 | Appointment as auditor (2013 waiver of appointment) |
1992 | Appointment as tax advisor (2022 waiver of appointment) |
1980 - 1987 | Westfälische Wilhelms-Universität Münster
|
Membership of other statutory supervisory boards | |
Fresenius Management SE (Fresenius Group mandate) | |
Membership of comparable German or foreign supervisory bodies | |
None |
Member of various supervisory bodies
Member of the Supervisory Board of Fresenius SE & Co. KGaA
Initial appointment: 2022
Current term of office: 2025– 2029

Date of Birth: | April 13, 1961 |
Place of Birth: | Stuttgart |
Nationality: | German |
Professional Experience
2018 – 2022 | Siemens Healthineers AG, Erlangen Member of the Managing Board Responsible for Imaging, Advanced Therapies, Technology & Innovation, Quality & Regulatory Affairs, Sustainability
|
2015 – 2018 | Siemens AG, Healthcare Sector, Erlangen
SVP, General Manager of Business Line Magnetic Resonance |
2014 – 2015 | Beckmann-Coulter – A Danaher Company, Miami (USA) SVP, Head of Business Unit Hematology and Urinalysis |
1998 – 2014 | Siemens AG, Healthcare Sector, Knoxville (USA)
|
2012 – 2014 | Siemens AG, Healthcare Sector, Knoxville (USA) CEO PETNET Solutions (Radiopharmaceuticals) |
1994 – 1998 | University of Tübingen Resident Physician Surgery |
1993 – 1994 | University of Frankfurt am Main Resident Physician Internal Medicine, Nuclear Medicine |
Education/Academic career
1995 | University Frankfurt am Main
Doctor of Medicine, M.D. (Dr.) |
1985 – 1992 | University Frankfurt am Main Studies in Medicine |
Membership of other statutory supervisory boards | |
Gerresheimer AG1 | |
Membership of comparable German or foreign supervisory bodies | |
None |
-
1 Stock listed company
Committees of the Supervisory Board of Fresenius SE & Co. KGaA
Wolfgang Kirsch (Chair)
Michael Diekmann
Susanne Zeidler
Susanne Zeidler (Chair)
Bernd Behlert
Grit Genster
Wolfgang Kirsch
Dr. Christoph Zindel
Dr. Dieter Schenk (Chair)
Michael Diekmann
Wolfgang Kirsch
Susanne Zeidler
The committee consists equally of two members each of the Supervisory Board of Fresenius SE & Co. KGaA and of Fresenius Management SE.
Additional information on the Supervisory Board of Fresenius SE & Co. KGaA
Rules of Procedure
Rules of Procedure
CVs of the Supervisory Board members
Meeting participation by individual
Members of the Supervisory Board of Fresenius Management SE
Chairman of the Supervisory Board of Fresenius SE & Co. KGaA
Former Chief Executive Officer of Deutsche Post DHL Group
Member of various Supervisory Boards
Member of various Supervisory Boards
Deputy Chairman
Member of supervisory bodies
Member of supervisory bodies
Contact
For blood donation and component processing, Fresenius Kabi offers medical devices. These include cell separators (apheresis systems), autotransfusion devices, blood bag and filter systems as well as related blood processing equipment. Component processing consists of the separation and collection of certain blood cells.
Blood Cell Separator
The Fresenius cell separator has three areas of application:
- Donate blood cells: obtaining cells from the blood of a donor for transfusion, for example for treating coagulation dysfunctions or leukemia patients
- Remove cancer cells: removing diseased cells or blood plasma from the blood of a patient with leukemia or an autoimmune disease, i. e., in patients with disorders where the body produces defense substances against its own cells
- Collect a patient’s cells: collecting cells from a patient's own blood for re-infusion, for example prior to operation.
A cell separator is primarily used to collect blood platelets or thrombocytes. While red blood cells mainly transport oxygen and other blood cells ward off pathogens, thrombocytes play an important role in blood clotting. Patients with too few thrombocytes suffer from an inability of the blood to coagulate properly. Injuries can lead to potentially dangerous bleeding. One example of the cause of thrombocyte deficiency is cancer therapy. Doctors infuse patients with healthy donor thrombocytes following treatment.
Thrombocytes are obtained most effectively with a blood cell separator. The machine, which works like a centrifuge, gently separates thrombocytes from the other blood components. Components that are not needed are immediately returned to the donor. Because only the thrombocytes are taken, which regenerate much quicker than red blood cells, a donor may donate much more frequently than in regular whole-blood donations. The cell separator also allows a much larger number of thrombocytes to be collected per donation than in whole blood. All patients who require a large number of thrombocytes can benefit double from the procedure – regular transfusions include thrombocytes from several sources but a blood cell separator can reduce the number of donors needed per transfusion. This allows a doctor to select thrombocytes from the most appropriate donors. This is important because the efficacy of the thrombocytes improves when the blood groups of donors and recipients match.
A cell separator can separate thrombocytes from other blood cells; it can also support the treatment of leukemia patients by removing diseased cells directly from the blood. Since leukemic cancer cells quickly reproduce, this procedure cannot heal a patient. But it relieves the strain on the kidneys by considerably lowering the number of destroyed cancer cells that must be removed from the blood following treatment.
Although rarely used, another application of the blood cell separator is quickly gaining in importance. Doctors can use the device to remove stem cells from the blood of a cancer patient. Through pre-treatment bone marrow stem cells start to reproduce and partially move into the blood stream. These stem cells can be collected almost like platelets. This way surgery to obtain stem cells directly from bone marrow can be avoided.
The treatment subsequently used to combat cancer cells damage the stem cells from which all other blood cells are made. If the patient receives healthy stem cells after chemotherapy, healthy blood cells can develop quicker, for example the platelets that are important for hemostasis and coagulation.
Blood bag systems
Blood bag systems are the foundation for worldwide blood supply by "classical" blood donation. More than 90 percent of all blood donations are processed in these systems that consist of up to six different bags with variable functions.
A combination of bags with venous cannulae and integrated needle protection, pre-donation sampling pouches and different filtration devices form the basis for highly professional whole blood collection systems. They allow producing different blood component preparations according to national and international standards. Blood donation and processing with these systems is supplemented by other devices such as automated scales and blood separators, sterile docking systems and sealers to name a few.
Contact
Fresenius Kabi AG
Else-Kröner-Str. 1
61352 Bad Homburg
Germany
T: +49 6172 686-0
communication@fresenius-kabi.com
Comprehensive patient care begins with prevention. Fresenius Helios' occupational healthcare centers offer a wide range of workplace prevention services. In addition, the Helios Prevention Center (HPC) of Fresenius Helios offers programs for individual prevention and company health management in the form of checkups and health coaching at numerous locations around Germany.
Occupational Healthcare
The aim of effective occupational healthcare is to maintain and promote health, prevent harmful influences resulting from working life, detect illnesses and damage to health at an early stage, as well as reintegrate employees into the workplace after a longer period of absence due to illness.
In Germany, Helios offers fully comprehensive occupational medical care with a fixed, permanent contact person at 17 occupational healthcare centers. This covers everything from legally required examinations, health protection and promotion to risk assessments and recommendations for optimal workplace design.
Spain's leading occupational risk prevention companies Fraterprevención, MC Prevención, Premap and Unipresalud complement the Quirónsalud network, with more than 150 centers throughout Spain and a presence in Latin America and the Middle East.
Helios Prevention Center (HPC)
A check-up at the Helios Prevention Center provides an accurate picture of one's own state of health. Our participants at one of our six locations benefit from short waiting times, short distances and holistic lifestyle advice.
The HPC qualifies participants to handle health issues with confidence and enables them to achieve a performance grade that can function as a model. Health conscious and competent leadership can act as a beacon to bind together and motivate employees. HPC views itself as a partner to companies that want to actively promote the health of their employees. From a one-day checkup at a Helios clinic to health workshops lasting several days at beautifully situated resorts – our modular program combines Helios quality with the ambience of exclusive hotels. Studies show occupational healthcare measures generate outstanding cost-benefit ratios.
Contact
Helios Prevention Center
Service-Hotline: 0800-633 49 46
info@helios-preventioncenter.de
Related Links
Fresenius Helios
Fresenius Vamed is a leading global provider of services for hospitals and other healthcare facilities. Its portfolio ranges from project development and planning to the total operational management of healthcare facilities and providing services to patients. The services are aimed at various areas of healthcare, ranging from prevention to acute care, rehabilitation, and nursing.
Headquartered in Vienna, Austria, Fresenius Vamed has successfully completed more than 1,000 healthcare projects in 101 countries on five continents since the company’s founding in 1982.
VAMED Value Chain
Project business:
- Project development
- Planning
- Project management and construction
Service business:
- Services (technical, commercial, infrastructural)
- Operational management (technical Management, total operational management)
The project business comprises the consulting, project development, planning, turnkey construction, and financing management of projects. VAMED responds flexibly to the local needs of clients, providing custom-tailored solutions all from one source. The company also carries out projects in cooperation with partners. Among public clients there is growing interest in public-private partnership (PPP) models. With 25 of these models, VAMED is a pioneer in this market segment.
VAMED offers a full range of facility management services for healthcare facilities. Modular in design, the company's service offering encompasses every aspect of technical, commercial, and infrastructural facility management. This ranges from building and equipment maintenance, medical technology management, and technical management through to the operational management. Its integrated portfolio of services is aimed at the optimal operation of a healthcare facility. VAMED was responsible for the total operational management of about 100 healthcare facilities on five continents with more about 18,000 beds. Worldwide, VAMED provides technical operation services to more than 840 hospitals with about 227,000 beds.
VAMED Vitality World’s thermal spa and wellness resorts have succeeded in bridging the gap between preventive medicine and healthcare tourism. With more than 3 million visitors annually in nine thermal spas and wellness resorts, VAMED is the market leader in Austria.
Vamed belongs to Fresenius SE & Co. KGaA healthcare group with a stake of about 77 percent and is one of the two Investment Companies of Fresenius.
Contact
VAMED Aktiengesellschaft
Sterngasse 5
1230 Vienna
Austria
office@vamed.com
+43 1 601 27-0
Helios is part of the Fresenius healthcare group and is Europe's leading private health care provider, with 128,000 employees. Fresenius Helios includes the Helios Group in Germany and Quirónsalud in Spain and Latin America. Every year about 26 million patients choose Helios for their medical treatment. In 2024, the company’s sales totaled more than €12.7 billion.
Helios Germany operates more than 80 hospitals, about 220 outpatient care centers with about 570 accredited doctor's licenses, six prevention centers and 27 occupational medicine centers. Helios treats approximately 5.5 million patients annually, of whom 4 million are outpatients. Since its beginnings, Helios has focused on measurable, high medical quality as well as data transparency and is better than the German average in more than 90 per cent of the quality targets. With about 78,000 employees, Helios generated sales of €7.7 billion in 2024. Helios Germany is headquartered in Berlin.
Quirónsalud operates 57 hospitals, including seven in Latin America, around 130 outpatient centers and more than 300 occupational risk prevention centers, and treats approximately 20 million patients annually, of whom 19 million are outpatients. Quirónsalud has about 50,000 employees and generated sales of more than €5 billion in 2024.
Contact
Helios Kliniken GmbH
Friedrichstr. 136
10117 Berlin
Germany
T +49 30 521 321-0
Fresenius is one of the top 40 companies in Germany in terms of market capitalization and is included in Germany's leading index, the DAX. We are also listed in the STOXX Europe 600 Health Care, the FTSEurofirst 300 and the DAXsector Pharma & Healthcare indices.
Fresenius ordinary shares are traded on the stock exchanges in Frankfurt, Düsseldorf and Munich.
At the end of July 2022, Fresenius SE & Co. KGaA's capital stock was 563,237,277 ordinary shares. The shares are notional no-par-value shares. Each share represents €1.00 of the capital stock.
Basic Share information
| Ordinary share | |
|---|---|
Securities identification no. | 578 560 |
Ticker symbol | FRE |
ISIN | DE0005785604 |
Bloomberg symbol | FRE GR |
Reuters symbol | FREG.de |
Main trading location | Frankfurt/Xetra |
Paying agent | Deutsche Bank AG, Taunusanlage 12, 60325 Frankfurt am Main, Germany |
Key data
| 2024 | 2023 | 2022 | |
|---|---|---|---|
Numbers of shares | 563,237,277 | 563,237,277 | 563,237,277 |
Stock exchange quotation1 in € | |||
High | 34.85 | 31.11 | 37.88 |
Low | 24.54 | 23.46 | 20.04 |
Year-end quotation | 33.54 | 28.07 | 26.25 |
Market capitalization2 in million € | 18,891 | 15,810 | 14,785 |
Total dividend distribution in million € | 5633 | - | 518 |
Dividend per share in € | 1.003 | - | 0.92 |
Earnings per share in €4 | 3.11 | 2.67 | 3.08 |
-
- 1 Xetra closing price on the Frankfurt Stock Exchange
- 2 Total number of ordinary shares multiplied by the respective Xetra year-end quotation on the Frankfurt Stock Exchange
- 3 Proposal
- 4 Net income attributable to shareholders of Fresenius SE & Co. KGaA; before special items
Contact
Vice President Investor Relations
Deputy Head of Investor Relations
T: +49 (0) 6172 608-5167
florian.feick@fresenius.com
Related Links
Interactive ToolEvent
November 05, 2025 - 01:30 pm | Bad Homburg, Germany
Nutrition is a topic which is all around us, day by day. While we often talk about obesity and weight loss diets we actually overlook that the opposite, meaning mal- or undernutrition, can be as detrimental. We talk about malnutrition when our body is not provided with sufficient energy and nutrients over several days. These nutrients, for example protein, carbohydrates, fats, vitamins and minerals, are necessary to ensure all essential functions of the body.
When our nutritional status is not optimal our body will get weaker in its reaction towards challenges, such as a disease, a cold or an infection. Improving our nutritional status will therefore support and protect our body.
Enteral Nutrition
Every normal form of nutrition is actually enteral. The word, which comes from the Greek “enteron,” or intestines, means, “using the gastrointestinal tract.” Enteral nutrition therapies are designed for patients who cannot nourish themselves sufficiently but still have an adequate digestive function. It is therefore ideal for patients who experience problems chewing or swallowing, loss of appetite, suffer from neurological or gastro-intestinal diseases, or are unconscious. Enteral nutrition is administered via sip feeds or also tube feeds.
If you are not able to eat enough, sip feed nutrition can help to make up for this deficit. Sip feed nutrition can be taken by mouth, swallowed and digested like normal food. It is flavorful, liquid food and contains all nutrients such as carbohydrates, fats and fiber as well as vitamins, minerals and trace elements.
Sip feed nutrition is balanced. It contains all the nutrients required by a person. Therefore, it can be drunk or eaten in addition to normal food but is also suitable as a sole source of nutrition.
Tube feed nutrition can help you to meet your nutritional needs in times when you are not able to eat enough.
Tube feeding is a procedure used for administering liquid nutrition directly into the stomach or small intestine. To do this, a thin tube (probe) is inserted either through the nose (nasal probe) or through the abdomen into the stomach.
Parenteral Nutrition
Patients who are given Fresenius Kabi infusion solutions receive all the components of balanced nutrition: carbohydrates, amino acids and fats as well as minerals, vitamins and trace elements. The composition of these nutritional solutions can be precisely balanced to feed a patient for any period of time.
Parenteral nutrition is necessary when the stomach or intestine – for instance due to an illness or operation – can no longer perform their tasks. A doctor may also decide that a patient should receive parenteral nutrition prior to an operation or during lengthy examinations when he or she is not allowed to eat. In intravenous nutrition, all key nutrients enter the bloodstream as molecular components. A patient can rely on parenterally given nutrients for a long period of time.
There are a number of liquids with a variety of compositions that can be used for parenteral nutrition therapy either on their own or as a mixture. When deciding on the best nutritional therapy, the general condition of the patient plays an important role, as well as a patient’s age and weight. There are also solutions for patients with kidney or liver disease that contain a special composition of amino acids. Fresenius Kabi offers amino acids and carbohydrates as single components but also as a combination that contains both nutritional elements. Three-chamber bags contain all three important nutrients including fats.
Carbohydrates are the most important source of energy
Carbohydrates are the most important source of energy in parenteral nutrition. Often, glucose alone is sufficient. Glucose is a "universal fuel" that can be utilized by all the body’s cells, making it a standard nutrient for parenteral nutrition. Doctors can choose between solutions with different glucose concentrations. Combined solutions also contain other nutritional components besides carbohydrates.
Amino acids are essential for parenteral nutrition
Amino acids are the smallest components of proteins that perform many tasks in the body. Every organ requires proteins for its structure and function. Proteins transport, act as messengers, fight germs or control and create vital metabolic reactions. They are also important building blocks for muscles, hair and finger nails, for example.
All proteins consist of different amino acids. Therefore, amino acids are also indispensable for parenteral nutrition. Fresenius Kabi offers solutions containing amino acids in an ideal composition that the body can use to generate the required proteins.
Fats contain lots of energy and essential fatty acids
Fats contain not only a lot of energy, but also important fatty acids that the body itself cannot produce. These essential fatty acids help build up cell membranes and transmitters that regulate the metabolism.
Patients who are fed parenterally receive the fats as microscopic droplets that are suspended in a liquid known as emulsion. When this emulsion is infused into the blood stream, the tiny droplets disperse in the blood and can be absorbed by the body's cells. Fat emulsions help doctors to provide critically-ill patients with quickly-available energy while offering a reliable source of essential fatty acids.
Contact
Fresenius Kabi AG
Else-Kröner-Str. 1
61352 Bad Homburg
Germany
T: +49 6172 686-0
communication@fresenius-kabi.com
Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used for the therapy and care of critically and chronically ill patients.
Its product portfolio comprises a range of highly complex biopharmaceuticals, clinical nutrition, medical technologies, and I.V. generic drugs. Within biopharmaceuticals, Fresenius Kabi offers, among others, biosimilar drugs with a focus on autoimmune diseases and oncology. The company’s clinical nutrition portfolio includes a wide selection of enteral and parenteral nutrition products. In the segment of medical technologies, Fresenius Kabi offers vital disposables, infusions pumps, apheresis machines, cell therapy devices, and more.
Following its “Vision 2026”, the company is furthermore committed to increase efficiencies in the therapy and care of patients and improve access to high-quality healthcare around the globe. Fresenius Kabi aspires to be leading globally in its product segments – all for the benefit of patients, its customers, and its stakeholders.
Fresenius Kabi employs over 40,000 people worldwide. In 2024 the company reported sales of more than €8 billion. Fresenius Kabi AG is a wholly owned subsidiary of the Fresenius SE & Co. KGaA healthcare group and one of the two Operating Companies of Fresenius.
Contact
Fresenius Kabi AG
Else-Kröner-Str. 1
61352 Bad Homburg
Germany
T: +49 6172 686-0
communication@fresenius-kabi.com